GI
MYGN icon

GAMMA Investing’s Myriad Genetics MYGN Stock Holding History

GAMMA Investing’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.24K Buy
984
+113
+13% +$477 ﹤0.01% 3719
2026
Q2 		$4.97K Sell
871
-580
-40% -$2.63K ﹤0.01% 3471
2026
Q1 		$6.53K Sell
1,451
-384
-21% -$2K ﹤0.01% 3261
2025
Q4 		$11.3K Buy
1,835
+189
+11% +$1.37K ﹤0.01% 2917
2025
Q3 		$11.9K Buy
1,646
+1,351
+458% +$8.02K ﹤0.01% 2797
2025
Q2 		$1.57K Sell
295
-209
-41% -$1.24K ﹤0.01% 3452
2025
Q1 		$4.47K Sell
504
-216
-30% -$2.59K ﹤0.01% 3126
2024
Q4 		$9.87K Sell
720
-900
-56% -$16.6K ﹤0.01% 2631
2024
Q3 		$44.4K Buy
1,620
+412
+34% +$11.2K ﹤0.01% 1573
2024
Q2 		$29.5K Sell
1,208
-10
-0.8% -$219 ﹤0.01% 1589
2024
Q1 		$26K Buy
1,218
+8
+0.7% +$172 0.01% 1463
2023
Q4 		$25.9K Buy
+1,210
New +$20.9K 0.01% 1321

Other funds holding MYGN

WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's MYGN Position: Q3 2026 in Review

GAMMA Investing increased its Myriad Genetics (MYGN) stake by 13% in Q3 2026, buying an estimated $477 and bringing the position to 984 shares worth $4.24K. The position accounts for ﹤0.01% of the portfolio, ranked #3719.

GAMMA Investing first reported a position in MYGN in Q4 2023 and has held it in 12 quarters since. The position peaked at $44.4K in Q3 2024. 3 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • GAMMA Investing held 984 shares of Myriad Genetics worth $4.24K as of Q3 2026.
  • GAMMA Investing bought 113 Myriad Genetics shares in Q3 2026, an estimated $477.
  • Myriad Genetics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3719 holding.
  • GAMMA Investing first reported a position in Myriad Genetics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Myriad Genetics position peaked at $44.4K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.